Korean Cancer Study Group 
Webzine Vol.25  SEP 2022 
논문 발간현황 2022.01 - 2022.08

▶ PC17-01 | PMID : 35622149

Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer  

Support Care Cancer. 2022 Sep;30(9):7431-7438.

DOI: 10.1007/s00520-022-07143-x


▶ HN17-11 | PMID : 35819451

A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)

Clin Cancer Res. 2022 Jul 12 (Online ahead of print)

DOI: 10.1158/1078-0432.CCR-22-1238



▶ BR16-09 | PMID : 35344650

Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)

Cancer Res Treat. 2022 Mar 24. (Online ahead of print)

DOI: 10.4143/crt.2021.1561.



▶ LU20-11 | PMID : 34705268

Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)

Cancer. 2022 Feb 15;128(4):778-787.

DOI: 10.1002/cncr.33984.



▶ HN13-01 | PMID : 34929077

Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)

Korean J Intern Med. 2022 Jan;37(1):190-200.

DOI: 10.3904/kjim.2020.636.



▶ ST19-16 | PMID : 35015188

Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)

Gastric Cancer. 2022 May;25(3):609-618.

DOI: 10.1007/s10120-021-01276-4.



▶ KPMNG 정밀의료 진료지침 | PMID : 34902959

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

Cancer Res Treat. 2022 Jan;54(1):1-9.

DOI: 10.4143/crt.2021.1115.